摘要
目的探讨培美曲塞联合顺铂治疗晚期肺腺癌的临床疗效及安全性。方法将52例晚期肺腺癌患者随机分入A组与B组,A组患者接受培美曲赛联合顺铂静脉注入治疗,B组患者接受多西他赛联合顺铂静脉注入治疗。治疗2个周期及6个周期后评估临床疗效,并比较2组临床疗效、中位生存期及不良反应。结果 A组与B组治疗2个周期时疾病控制率差异无统计学意义(P>0.05),治疗6个周期时A组患者疾病控制率显著高于B组(P<0.05)。A组与B组1年生存率分别为46.4%和37.5%(P>0.05),中位生存期分别为10.2个月和9.7个月(P>0.05)。血液学毒性、消化道反应及肝肾功能损害是2组的常见不良反应,其中A组血液学毒性发生率显著低于B组(P<0.05)。结论培美曲塞或多西他赛联合顺铂治疗晚期肺腺癌临床疗效相当,但培美曲塞安全性更为理想,患者耐受性好。
Objective To explore the efficacy and safety of pemetrexed combined with cisplatin for advanced lung ade -nocarcinoma .Methods 52 cases of advanced lung adenocarcinoma were randomly divided into group A and group B .Group A was given pemetrexed combined with cisplatin administered intravenously .Group B received docetaxel and cisplatin administered intravenously .The clinical effects were evaluated on 2 cycles and 6 cycles after treatments .Clinical effect , median survival time and adverse reactions were compared between the 2 groups.Results There were no significant difference in disease control rate between group A and group B on 2 cycles after treatment (96.4%vs 91.7%,P>0.05);The disease control rate in group A on 6 cycles after treatment was much higher than that of group B (46.4% vs 20.8%,P<0.05);1-year survival rate were 46.4%and 37.5%(P>0.05),median survival time was 10.2 months and 9.7 months in group A and group B(P>0.05);Hematologic toxicities,gastrointestinal reactions and liver renal toxicity were the main adverse reactions in 2 groups.The hematologic toxicities and gastrointestinal reactions in group A were much lower than those of group B (P<0.05).Conclusion Pemetrexed or do-cetaxel combined with cisplatin showed similar efficacy for advanced lung adenocarcinoma .Pemetrexed has better safety and toler-ability.
出处
《实用癌症杂志》
2014年第12期1589-1591,共3页
The Practical Journal of Cancer
关键词
肺腺癌
培美曲塞
顺铂
多西他赛
Lung adenocarcinoma
Pemetrexed
Cisplatin
Docetaxel
